A Combined Chemical, Computational, and In Vitro Approach Identifies SBL-105 as Novel DHODH Inhibitor in Acute Myeloid Leukemia Cells

Abstract

Inhibition of the dihydroorotate dehydrogenase (DHODH) has been successful at the preclinical level in controlling myeloid leukemia. However, poor clinical trials warrant the search for new potent DHODH inhibitors. Herein we present a novel DHODH inhibitor SBL-105 effective against myeloid leukemia. Chemical characteristics were identified by 1H NMR, 13C NMR, and Mass-spectroscopy. Virtual docking and molecular dynamic simulation analysis were performed using the automated protocol with AutoDock -VINA, GROMACS program. Human-recombinant (rh) DHODH was used for enzyme inhibition study. THP-1, TF-1, HL-60 and SKM-1 cell lines were used. MTT assay was used to assess cell viability. Flow cytometry was employed for cell cycle, apoptosis, and differentiation analysis. Chemical analysis identified the compound to be 3-benzylidene-6,7-benz-chroman-4-one (SBL-105). The compound showed high binding efficacy towards DHODH with a ΔGbinding score of -10.9 kcal/mol. Trajectory analysis indicated conserved interactions of SBL-105-DHODH to be stable throughout the 200ns simulation. SBL-105 inhibited rh DHODH with an IC50 value of 48.48 nM. The GI50 values of SBL-105 in controlling THP-1, TF-1, HL-60 and SKM-1 cell proliferations were 60.66 nM 45.33 nM, 73.98 nM and 86.01 nM respectively. A dose-dependent increase in S-phase cell cycle arrest and total apoptosis was observed by SBL-105 treatment in both cell types, which were reversed in the presence of uridine. The compound also increased the differentiation marker CD11b positive populations in both THP-1 and TF-1 cells, which were decreased under uridine influence. SBL-105, a novel DHODH inhibitor, identified using computational and in vitro analysis, was effective controlled AML cells and needs attention for further preclinical developments.

In silico analysis of TUBA4A mutations in Amyotrophic Lateral Sclerosis to define mechanisms of microtubule disintegration

“…The Prime MM-GBSA module was then used to estimate the binding free energy (ΔG) of GTP binding 33 . GTP docking to mutant dimers using the Autodock-Vina package was conducted using SiBDock from https://sibiolead.com/ 34 , 35 .…”

Computational and Preclinical Analysis of 2-(4-Methyl)benzylidene-4,7-dimethyl Indan-1-one (IPX-18): A Novel Arylidene Indanone Small Molecule with Anti-Inflammatory Activity via NF-κB and Nrf2 Signaling

“…IPX structure was also prepared using Discovery Studio Visualizer. Docking was performed using SiBDOCK web server at (accessed on 3 September 2020), which uses autodock vina docking protocol [ 26 , 27 ]. Docking grid box was set to focus on p50’s DNA-binding region, and box dimension was set to 20.…”

Discovery of Nanomolar Inhibitors for Human Dihydroorotate Dehydrogenase Using Structure-Based Drug Discovery Methods

“…The use of virtual screening methodologies to expedite the drug development timeline have gained momentum over recent years by substantially reducing the number of ligands that will need to be validated through experimental assays . Previously, our group and others have successfully implemented SBDD to identify small molecule binders for infectious and neurodegenerative diseases, cancer, heart failure, and various other acute conditions. ,,− …”